申请人:Dr. Karl Thomae GmbH
公开号:US04550107A1
公开(公告)日:1985-10-29
Disclosed are novel condensed diazepinones of formula I ##STR1## wherein B is a fused ring selected from ##STR2## X is --CH-- or, when B is ortho-phenylene, X can also be nitrogen; A.sub.1 is C.sub.1 -C.sub.2 alkylene; A.sub.2 is C.sub.1 -C.sub.2 when it is in the 2-position relative to the saturated heterocyclic ring nitrogen or a single bond or methylene when it is in the 3- or 4-position; R.sub.1 is C.sub.1 -C.sub.3 alkyl; R.sub.2 is C.sub.1 -C.sub.7 alkyl, optionally hydroxy-substituted on at least one of its second to seventh carbon, or C.sub.3 -C.sub.7 cycloalkyl, optionally hydroxy substituted, or C.sub.3 -C.sub.7 cycloalkylmethyl; or R.sub.1 and R.sub.2 can, together with the nitrogen therebetween, be a 4- to 7-membered saturated monocyclic, heterocyclic ring which can optionally include an oxygen or N--CH.sub.3 ; R.sub.3 is hydrogen, chlorine, or methyl; R.sub.4 is hydrogen or C.sub.1 -C.sub.4 alkyl, R.sub.5 is hydrogen, chlorine or C.sub.1 -C.sub.4 alkyl; and Z is a single bond, oxygen, methylene or 1,2-ethylene; and NR.sub.1 R.sub.2 --N oxides and nontoxic, pharmaceutically acceptable addition salts thereof. Also disclosed are pyrrolobenzodiazepinone intermediates, pharmaceutical compositions containing the condensed diazepinones and methods of using them to treat cardiovascular disorders, particularly bradycardia and bradyarrhythmia.
揭示了式I的新型缩合二氮杂环酮##STR1##其中B是从##STR2##中选择的融合环;X是--CH--或者当B是邻苯二甲烷时,X也可以是氮;A.sub.1是C.sub.1-C.sub.2烷基;A.sub.2是C.sub.1-C.sub.2,当它相对于饱和杂环环氮位于2位时,或者是单键或亚甲基,当它位于3位或4位时;R.sub.1是C.sub.1-C.sub.3烷基;R.sub.2是C.sub.1-C.sub.7烷基,其至少在第二到第七碳上可选择地被羟基取代,或者是C.sub.3-C.sub.7环烷基,可选择地被羟基取代,或者是C.sub.3-C.sub.7环烷基甲基;或者R.sub.1和R.sub.2可以与其之间的氮一起形成一个4到7成员的饱和单环杂环,可选择地包括氧或N--CH.sub.3;R.sub.3是氢、氯或甲基;R.sub.4是氢或C.sub.1-C.sub.4烷基,R.sub.5是氢、氯或C.sub.1-C.sub.4烷基;Z是单键、氧、亚甲基或1,2-乙烯基;以及NR.sub.1 R.sub.2 --N氧化物和其无毒、药学上可接受的加合盐。还揭示了吡咯苯二氮杂环酮中间体、含有缩合二氮杂环酮的药物组合物以及使用它们治疗心血管疾病,特别是心动过缓和心动过缓性心律失常的方法。